共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
Li Ming Zhu Dong Mei Shi Qiang Dai Xiao Jiao Cheng Wei Yan Yao Ping Hu Sun Yan Fei Ding Min Min Qiao Yun Lin Wu Shi Hu Jiang Shui Ping Tu 《Oncotarget》2014,5(14):5403-5415
X-linked inhibitor of apoptosis (XIAP)-associated factor 1 (XAF1), a XIAP-binding protein, is a tumor suppressor gene. XAF1 was silent or expressed lowly in most human malignant tumors. However, the role of XAF1 in hepatocellular carcinoma (HCC) remains unknown. In this study, we investigated the effect of XAF1 on tumor growth and angiogenesis in hepatocellular cancer cells. Our results showed that XAF1 expression was lower in HCC cell lines SMMC-7721, Hep G2 and BEL-7404 and liver cancer tissues than that in paired non-cancer liver tissues. Adenovirus-mediated XAF1 expression (Ad5/F35-XAF1) significantly inhibited cell proliferation and induced apoptosis in HCC cells in dose- and time- dependent manners. Infection of Ad5/F35-XAF1 induced cleavage of caspase -3, -8, -9 and PARP in HCC cells. Furthermore, Ad5/F35-XAF1 treatment significantly suppressed tumor growth in a xenograft model of liver cancer cells. Western Blot and immunohistochemistry staining showed that Ad5/F35-XAF1 treatment suppressed expression of vascular endothelial growth factor (VEGF), which is associated with tumor angiogenesis, in cancer cells and xenograft tumor tissues. Moreover, Ad5/F35-XAF1 treatment prolonged the survival of tumor-bearing mice. Our results demonstrate that XAF1 inhibits tumor growth by inducing apoptosis and inhibiting tumor angiogenesis. XAF1 may be a promising target for liver cancer treatment. 相似文献
3.
Jun Cheng Hai-Yang Xie Xiao Xu Jian Wu Xuyong Wei Rong Su Wu Zhang Zhen Lv Shusen Zheng Lin Zhou 《Cancer letters》2011
N-myc downstream-regulated gene 1 (NDRG1) has been reported to be a multifunctional protein associated with carcinogenesis, however, the cellular function of NDRG1 remains elusive in human cancers. Here, our proteomics profile analysis of HCC tissues with different metastatic capabilities revealed that NDRG1 was correlated with metastasis and recurrence in HCC patients after liver transplantation (LT). Immunohistochemical staining of 143 HCC patients after LT showed that NDRG1-positive expression had poor prognosis, either for shorter disease-free survival or overall survival (P < 0.001), compared with NDRG1-negative expression. Multivariate analysis confirmed NDRG1 as an independent prognostic value (P < 0.001). In addition, in vitro experiments HCC cells with small interfering RNA against NDRG1 significantly suppressed its proliferation, colony formation, invasion and migration ability. Microarray analysis revealed that NDRG1 modulated the expression of genes associated with transmembrane transporter activity, chemoattractant activity, immune response, cell adhesion and cell proliferation process. Taken together, these results suggested that NDRG1 was an important molecule in controlling HCC metastasis and thus suggested as a novel biomarker for predicting HCC recurrence after LT. 相似文献
4.
5.
6.
Keun Na Seul‐Ki Jeong Min Jung Lee Sang Yun Cho Sun A Kim Min‐Ji Lee Si Young Song Hoguen Kim Kyung Sik Kim Hyun Woong Lee Young‐Ki Paik 《International journal of cancer. Journal international du cancer》2013,133(2):408-415
Although alpha‐fetoprotein (AFP) is currently the major serologic biomarker for hepatocellular carcinoma (HCC), it cannot efficiently distinguish this cancer from other forms of liver disease in early diagnosis due to its low sensitivity. The aim of this study is to compare sensitivity and specificity of human carboxylesterase 1 (hCE1) and AFP biomarker. Antibody‐based assays for hCE1 and AFP were used to test both biomarkers with respect to diagnostic efficiency, Youden's index and the area under the curve (AUC) through receiver operating characteristic (ROC) analysis in plasma from 208 patients with HCC (n=57), liver cirrhosis (n=27), chronic hepatitis (n=37), cholangiocarcinoma (n=22), gastric cancer (n=31) and pancreatic cancer (n=34), along with 52 healthy donors (HDs). The levels of hCE1 were significantly higher in patients with HCC than HDs and the other diseases (p<0.005), further verified by AUC values and Youden's index. In the set of HCC versus liver cirrhosis the AUC values were 0.744 (AFP), 0.918 (hCE1) and 0.938 (combination of AFP and hCE1), respectively. These results indicate that hCE1 is not only a more potent and specific marker in distinguishing cancer from liver diseases, in particular cirrhosis, but the combination of hCE1 and AFP shows also synergistic potential for greater sensitivity and specificity in early diagnosis. Therefore the antibody‐based hCE1 assay appears to have high diagnostic efficiency for discriminating HCC from other forms of liver disease. It is now feasible to further validate this novel plasma‐based biomarker in the large cohort we assembled. 相似文献
7.
The extraordinary developments made in the past decade in proteomic technologies, in particular in mass spectrometry, have enabled investigators to consider designing studies to search for diagnostic and therapeutic biomarkers by scanning complex proteome samples. We developed a method based on extensive fractionation of intact proteins, to comprehensively and quantitatively profile the liver and plasma proteomes in health and disease. We have applied this method to samples collected from patients with early hepatocellular carcinoma (HCC) and from patients with liver cirrhosis as well as to samples collected from three mouse models of HCC. This method allowed for the identification of proteins that differ in expression levels in liver tissue or in plasma with disease progression from liver fibrosis, cirrhosis or steatohepatitis to HCC. The comparative analysis of the liver and plasma proteomes generated from human and mouse specimens, constitutes a novel and powerful strategy for HCC biomarker discovery. 相似文献
8.
骨桥蛋白检测对预测肝细胞癌转移复发的意义 总被引:4,自引:0,他引:4
背景与目的:骨桥蛋白(osteopontin,OPN)是一种分泌性磷酸糖蛋白,可以同整合素和CD44v结合,在肿瘤发生、发展、侵袭、转移等病理过程中起作用。本研究探讨血浆中OPN检测,在预测肝细胞肝癌(hepatocellularcarcinoma,HCC)术后转移复发中的意义。方法:病例组选取手术切除的肝细胞癌患者56例,用ELISA法检测术前血浆OPN浓度,对照组取23例健康体检职工血浆标本。比较病例组与对照组血浆OPN水平;并随访病例组复发转移情况,分析血浆OPN水平与肿瘤转移复发的关系。结果:HCC组血浆OPN浓度为(864.4±391.9)!g/L,健康对照组血浆OPN浓度为(382.5±169.4)!g/L,两组相比较存在显著性差异(P<0.001)。随访期间,25例无复发,31例复发。肝细胞癌无复发组血浆OPN浓度为(744.6±323.9)!g/L,复发组血浆OPN浓度为(961.0±411.6)!g/L,复发组与无复发组血浆OPN浓度比较有显著性差异(P=0.039)。Cox模型多因素分析发现血浆OPN水平、肝硬化、肿瘤大小是预测肝癌转移复发的独立因素。结论:肝细胞癌患者血浆中OPN浓度可以作为预测肿瘤复发转移的潜在参考分子指标之一。 相似文献
9.
Tumor HLA-DR expression linked to early intrahepatic recurrence of hepatocellular carcinoma 总被引:3,自引:0,他引:3
Matoba K Iizuka N Gondo T Ishihara T Yamada-Okabe H Tamesa T Takemoto N Hashimoto K Sakamoto K Miyamoto T Uchimura S Hamamoto Y Oka M 《International journal of cancer. Journal international du cancer》2005,115(2):231-240
10.
Tao Si Xuejian Ning Haihui Chen Zhengguo Hu Linglu Dun Na Zheng Ping Huang Liu Yang Ping Yi 《Journal of gastrointestinal oncology.》2021,12(6):3079
BackgroundWith high incidence and mortality rates, hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors worldwide. Chronic hepatitis B virus (HBV) infection is a leading cause of HCC, especially for Asians and blacks. However, the molecular mechanisms underlying HBV-related HCC are unclear. This study sought to identify novel prognostic biomarkers and explore the potential pathogenesis of HBV-related HCC.MethodsThe gene expression profiles and corresponding clinical information of HCC from The Cancer Genome Atlas Liver Hepatocellular Carcinoma data set were analyzed by a weighted gene co-expression network analysis. Correlations between the co-expression modules and clinical traits were calculated. Next, key modules associated with HBV infection were identified. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were conducted for the genes in the key modules. The hub genes were identified based on the protein-protein interaction (PPI) network via the Cytoscape. Finally, an overall survival (OS) analysis was performed.ResultsThe two modules (i.e., the brown and yellow modules) most relevant to HBV infection were constructed. A functional enrichment analysis revealed that the genes in the two modules were mainly enriched in HCC-related pathways, such as the phosphatidylinositol-3-kinase and protein kinase B signaling pathway, focal adhesion, human papillomavirus infection, the Rap1 signaling pathway, and the cyclic guanosine monophosphate-dependent protein kinase (cGMP-PKG) signaling pathway. Ten hub genes [i.e., COL3A1, ANTXR1, COL14A1, THBS2, ADAMTS2, AEBP1, PRELP, EMILIN1, DCN and PODN] in the brown module, and 10 hub genes [i.e., USP34, SEC24C, ZNF770, STAG1, TSTD2, PKD1P6, CCNK, GFT2I, NT5C2 and SMG6] in the yellow module were identified. Among the hub genes, ANTXR1 (Anthrax-toxin receptor 1) was significantly correlated with HBV-related HCC patients’ OS.ConclusionsANTXR1 represents a potential therapeutic target for HBV-related HCC. This study offers novel insights into the molecular mechanisms of HBV-induced tumorigenesis, which needs to be further validated by basic experiments and large-scale cohort studies. 相似文献
11.
12.
Metallothionein 1 family profiling identifies MT1X as a tumor suppressor involved in the progression and metastastatic capacity of hepatocellular carcinoma
下载免费PDF全文
![点击此处可从《Molecular carcinogenesis》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Zhikun Liu MD Qianwei Ye MD Lingjiao Wu MD Feng Gao MD Haiyang Xie PhD Lin Zhou PhD Shusen Zheng MD PhD FACS Xiao Xu MD PhD 《Molecular carcinogenesis》2018,57(11):1435-1444
13.
目的检测WFDC-1基因在肝癌和正常肝组织的表达差异并探讨其临床意义。方法采用荧光实时定量PCR(FQ-RT-PCR)法检测30例肝癌组织及相应远端正常肝组织WFDC-1mRNA的表达,分析其表达与肝癌患者临床特征的相关性。结果 WFDC-1mRNA在肝癌组织中的表达水平(0.050±0.026)明显低于远端正常肝组织(0.113±0.040),两者差别有统计学意义(P〈0.05)。WFDC-1mRNA在肝癌中的表达水平与HBsAg水平有关,合并HBsAg阳性的肝细胞癌(HCC)中的表达低于HBsAg阴性HCC组(P〈0.05),而与年龄、性别、肿瘤大小、临床分期、AFP及有无肝硬化无关(P〉0.05)。结论肝癌组织中WFDC-1基因表达水平明显低于相应正常肝组织,提示WFDC-1表达与降低肿瘤发生有一定的相关性,为潜在的抑癌基因。 相似文献
14.
15.
Youli Du Xiaoou Ma Dongxu Wang Yuguang Wang Tianyu Zhang Lianjie Bai Yunlong Liu Shaosen Chen 《Journal of gastrointestinal oncology.》2021,12(5):2361
BackgroundHepatocellular carcinoma (HCC) is the most common type of liver cancer with a high mortality rate. However, spliceosomal genes are still lacking in the diagnosis and prognosis of HCC.MethodsIdentification of differentially expressed genes (DEGs) was performed using the limma package in R software. Modules highly related to HCC were obtained by weighted gene co-expression network analysis (WGCNA), and the module genes were analyzed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway. The biomarker for diagnosing HCC was determined by receiver operating characteristic (ROC) curve analysis, and the effect of the biomarker in the diagnosis of HCC was evaluated by performing five-fold cross-validation with logistic regression. HCC specimens from preoperatively treated patients were tested for biomarker by real-time quantitative polymerase chain reaction (RT-qPCR). Kaplan-Meier analysis was used to assess the relationship between biomarker and patient survival. The role of biomarker was evaluated using ESTIMATE analysis in the tumor microenvironment.ResultsIn this study, 389 DEGs were screened out from three Gene Expression Omnibus (GEO) datasets. We also found that the turquoise module of 123 genes from The Cancer Genome Atlas (TCGA) data was the key module with the highest correlation with HCC traits. Then, 123 genes were analyzed using the KEGG enrichment pathway, and eight genes were found to be most significantly related to the spliceosome pathway. We selected 8 genes and 389 DEGs shared genes, and finally got the only gene, heterogeneous nuclear ribonucleoprotein (hnRNPU). The high expression of hnRNPU was associated with poor prognosis of HCC, and hnRNPU was a biomarker for diagnosing HCC. In the tissues of patients with excellent HCC treatment hnRNPU messenger RNA (mRNA) was lower than in the tissues of patients with poor HCC treatment. High expression of hnRNPU was significantly increased in HCC patients with low stromal (P<0.05), low immune (P<0.05), and low estimation scores (P<0.05), and with high tumor purity (P<0.05) and high malignant progression (P<0.05) of the HCC.ConclusionsThe hnRNPU gene identified in this study may become a new biomarker for the diagnosis and prognosis of HCC. 相似文献
16.
Li Guo Lijun Wan Youwen Hu Hongyan Huang Bo He Zhili Wen 《Journal of gastrointestinal oncology.》2022,13(1):344
BackgroundChanges in N-glycosylation of proteins are thought to play a key role in cancer. This study aims to investigate the changes in the serum N-glycan profiles of patients with hepatitis B virus (HBV)-related liver disease, and to evaluate the role of N-glycan markers in the noninvasive diagnosis of hepatocellular carcinoma (HCC).MethodsSerum samples were available for 21 patients with HCC, 20 patients with liver cirrhosis (LC), 20 patients with chronic hepatitis B (CHB), and 20 healthy subjects. Serum N-glycans were released and analyzed using DNA sequencer-assisted fluorophore-assisted carbohydrate electrophoresis (DSA-FACE). Serum AFP was determined by electrochemiluminescence (ECL) (AFP reference value range: <10 ng/mL).ResultsThere were characteristic changes in the serum N-glycan profiles of patients with HBV-related liver disease, including NA2FB, NA3, and NA3Fb. NA2FB was the most abundant in LC patients, while NA3Fb abundance was the highest in HCC patients. For HCC screening in patients, especially in patients with LC, the sensitive of Log peak 9 (94.4%) and Log (peak 9/peak 7) (88.9%) were better than alpha-fetoprotein (AFP) (33.3–61.1%), and their specificity was similar to that of AFP. The receiver operating characteristic (ROC) curve showed that the accuracy of Log peak 9 (AUC: 0.81±0.07) and Log (peak 9/peak 7) (AUC: 0.87±0.06) was better than that of AFP (AUC: 0.72±0.09), while the accuracy of AFP combined with the above 2 indexes was better than that of a single index. Moreover, Log (peak 9/peak 7) combined with AFP (AUC: 0.89±0.06) had the best accuracy in the diagnosis of HCC.ConclusionsOur research indicates that N-glycan may serve a new, valuable, and noninvasive alternative method for diagnosing HCC, and it may be a supplement to AFP in the diagnosis of HCC in patients with HBV-related liver disease. 相似文献
17.
18.
19.